CDH2 and neoplasm: These TFs act to suppress the expression of epithelial markers such as E-cadherin, as well as activation of mesenchymal markers such as N-cadherin, Vimentin, matrix metalloproteinases, favoring tumor infiltration, dissemination, and metastasis associated with increased resistance to apoptosis (bcl-2) contributing to the poor prognosis of patients [45,46].